Treasury
3-MO 4.17% +3bp 6-MO 4.27% +3bp 1-YR 4.45% +1bp 2-YR 4.76% unch 3-YR 4.82% -1bp 5-YR 4.83% -3bp 7-YR 4.89% -4bp 10-YR 4.96% -5bp 20-YR 5.33% -5bp 30-YR 5.29% -5bp 3-MO 4.17% +3bp 6-MO 4.27% +3bp 1-YR 4.45% +1bp 2-YR 4.76% unch 3-YR 4.82% -1bp 5-YR 4.83% -3bp 7-YR 4.89% -4bp 10-YR 4.96% -5bp 20-YR 5.33% -5bp 30-YR 5.29% -5bp 3-MO 4.17% +3bp 6-MO 4.27% +3bp 1-YR 4.45% +1bp 2-YR 4.76% unch 3-YR 4.82% -1bp 5-YR 4.83% -3bp 7-YR 4.89% -4bp 10-YR 4.96% -5bp 20-YR 5.33% -5bp 30-YR 5.29% -5bp 3-MO 4.17% +3bp 6-MO 4.27% +3bp 1-YR 4.45% +1bp 2-YR 4.76% unch 3-YR 4.82% -1bp 5-YR 4.83% -3bp 7-YR 4.89% -4bp 10-YR 4.96% -5bp 20-YR 5.33% -5bp 30-YR 5.29% -5bp 3-MO 4.17% +3bp 6-MO 4.27% +3bp 1-YR 4.45% +1bp 2-YR 4.76% unch 3-YR 4.82% -1bp 5-YR 4.83% -3bp 7-YR 4.89% -4bp 10-YR 4.96% -5bp 20-YR 5.33% -5bp 30-YR 5.29% -5bp 3-MO 4.17% +3bp 6-MO 4.27% +3bp 1-YR 4.45% +1bp 2-YR 4.76% unch 3-YR 4.82% -1bp 5-YR 4.83% -3bp 7-YR 4.89% -4bp 10-YR 4.96% -5bp 20-YR 5.33% -5bp 30-YR 5.29% -5bp
US Treasury par yield curve · Sep 21 · Source: U.S. Treasury
Monday, September 21, 2026
U.S. Edition
MONEY & WORLD
Subscribe
Biotechnology asset sale

Sangamo completes $111m sale of Fabry gene therapy assets from Chapter 11

Money & World
The Editorial Team ·
A masked laboratory worker in protective clothing enters a sterile cleanroom. Stock photo
Stock photo. Not the actual scene. Photo: Policarpo Brito / Pexels

Sangamo Therapeutics completed the sale of its ST-920 Fabry disease gene therapy assets to PTC Therapeutics, according to a Form 8-K filed Monday afternoon. PTC paid $111m in cash at closing and may pay up to another $100m if specified milestones are met.

The sale is complete. PTC was selected at an August 10 court-supervised auction, and the Delaware bankruptcy court approved the deal September 2. Sangamo, which filed for Chapter 11 on June 23, closed the transaction September 17.

The assets center on isaralgagene civaparvovec, also called ST-920, a one-time gene therapy candidate for Fabry disease. PTC also assumed specified liabilities. Sangamo's stock was suspended from Nasdaq in May, trades on the OTCID Basic Market as SGMOQ and is scheduled for delisting September 27.

The filing warns that the shares are highly speculative and may bear little or no relationship to any recovery in the bankruptcy case.

The document: Sangamo Therapeutics, Form 8-K, September 21, 2026.

More on Finance